Last reviewed · How we verify
Conversion of Atrial Fibrillation/Flutter
Approved treatments
- Tikosyn · Pfizer Inc.
Blocks cardiac potassium channel IKr to prolong repolarization and delay arrhythmia recurrence.
Clinical guidelines
- FDA label — 1L
TIKOSYN is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Conversion of Atrial Fibrillation/Flutter patent landscape — cliff calendar, originator estates, attackable patents
- Conversion of Atrial Fibrillation/Flutter treatment landscape brief
- Conversion of Atrial Fibrillation/Flutter treatment updates RSS
Frequently asked questions about Conversion of Atrial Fibrillation/Flutter
What drugs treat Conversion of Atrial Fibrillation/Flutter?
Tracked treatments include Tikosyn.
What is the treatment for Conversion of Atrial Fibrillation/Flutter?
Standard treatment for Conversion of Atrial Fibrillation/Flutter includes Tikosyn. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Conversion of Atrial Fibrillation/Flutter?
FDA label publishes guidelines for Conversion of Atrial Fibrillation/Flutter. 1 guideline references tracked.
Related
- Treatment landscape: Conversion of Atrial Fibrillation/Flutter patent cliff · Conversion of Atrial Fibrillation/Flutter CI report
- Treatment: Tikosyn · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing